Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 7/20 | 0.43 |
| ▸ | CDK9 | P50750 | 7/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3434496 | 0.88 | SIGMAR1 (0.40) | CCNT1CDK9SIGMAR1KDM4EMAPT | |
| SCHEMBL3436613 | 0.85 | SIGMAR1 (0.42) | CCNT1CDK9SIGMAR1KDM4EWNT3A | |
| SCHEMBL3435651 | 0.82 | SIGMAR1 (0.37) | CCNT1CDK9SIGMAR1KDM4ELMNA | |
| SCHEMBL3436712 | 0.81 | CDK9 (0.42) | CCNT1CDK9SIGMAR1KDM4EWNT3A | |
| SCHEMBL3436698 | 0.79 | CDK9 (0.55) | CCNT1CDK9SIGMAR1 | |
| SCHEMBL3435686 | 0.78 | SIGMAR1 (0.42) | CCNT1CDK9SIGMAR1KDM4EMAPT | |
| SCHEMBL3436504 | 0.77 | CDK9 (0.53) | CCNT1CDK9SIGMAR1WNT3ALMNA | |
| SCHEMBL3436614 | 0.76 | CCNT1 (0.48) | CCNT1CDK9SIGMAR1KDM4EWNT3A | |
| SCHEMBL3436391 | 0.75 | KDM4E (0.45) | CCNT1CDK9SIGMAR1KDM4EWNT3A | |
| SCHEMBL3436026 | 0.75 | CCNT1 (0.41) | CCNT1CDK9SIGMAR1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | CCNT1 3047/4885CDK9 648/4885SIGMAR1 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.